Attached files
file | filename |
---|---|
EX-99.2 - POSTER SESSION - Cellular Biomedicine Group, Inc. | cbmg_ex992.htm |
EX-99.1 - PRESENTATION - Cellular Biomedicine Group, Inc. | cbmg_ex991.htm |
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 8-K
CURRENT REPORT
Pursuant to Section 13 or 15(d) of the Securities Exchange Act of
1934
Date of Report (Date of earliest event reported): December 8,
2016
CELLULAR BIOMEDICINE GROUP, INC.
(Exact
name of registrant as specified in its charter)
Delaware
|
|
001-36498
|
|
86-1032927
|
(State
or other Jurisdiction of Incorporation)
|
|
(Commission
File Number)
|
|
(IRS
Employer Identification No.)
|
19925 Stevens Creek Blvd., Suite 100
Cupertino, California
|
|
95014
|
(Address
of Principal Executive Offices)
|
|
(Zip
Code)
|
Registrant’s
telephone number, including area code: (408) 973-7884
(Former
name or former address, if changed since last report.)
Check
the appropriate box below if the Form 8-K filing is intended to
simultaneously satisfy the filing obligation of the registrant
under any of the following provisions:
☐
|
Written
communications pursuant to Rule 425 under the Securities Act (17
CFR 230.425)
|
☐
|
Soliciting
material pursuant to Rule 14a-12 under the Exchange Act (17 CFR
240.14a-12)
|
☐
|
Pre-commencement
communications pursuant to Rule 14d-2(b) under the Exchange Act (17
CFR 240.14d-2(b))
|
☐
|
Pre-commencement
communications pursuant to Rule 13e-4(c) under the Exchange Act (17
CFR 240.13e-4(c))
|
Item 7.01 Regulation FD Disclosure.
Attached as Exhibits 99.1 and 99.2 to this Current Report is the
form of presentation and poster session, respectively, that
Cellular Biomedicine Group, Inc. (the “Company”) used
in connection with the Company’s presentation of its
developments of haMPC as a disease modifying therapy for
Osteoarthritis patients, including a comparitive preclinical study
on the efficiancy and biodistribution of autologous, allogeneic and
xenogeneic adipose mesenchymal stem cells on osteoarthritis and
interim three-month safety data for the Company’s Phase I
clinical trial for AlloJoinTM Off-the-Shelf
Allogeneic Stem Cell Therapy for Knee Osteoarthritis at the World
Stem Cell Summit held in West Palm Beach, Florida on December 8,
2016.
Item 9.01. Financial Statements and Exhibits.
(d) Exhibits
99.1
Presentation
99.2 Poster
Session
SIGNATURE
Pursuant to the
requirements of the Securities Exchange Act of 1934, the registrant
has caused this report to be signed on its behalf by the
undersigned hereunto duly authorized.
|
Cellular Biomedicine Group, Inc.
|
|
|
|
|
|
|
Date:
December 8, 2016
|
By:
|
/s/
Bizuo (Tony) Liu
|
|
|
|
Bizuo
(Tony) Liu
Chief
Financial Officer
|
|
|
|
|
|